The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age
- 9 May 2015
- journal article
- research article
- Published by Springer Nature in Biogerontology
- Vol. 17 (1) , 177-187
Abstract
Many subunit vaccines require adjuvants to improve their limited immunogenicity. Various adjuvant candidates targeting toll-like receptors (TLRs) are currently under development including the synthetic TLR4 agonist glucopyranosyl lipid A (GLA). GLA has been investigated in the context of influenza vaccine, which is of particular importance for the elderly population. This study investigates the effect of GLA on antigen-presenting cells from young (median age 29 years, range 26–33 years) and older (median age 72 years, range 61–78 years) adults. Treatment with GLA efficiently increases the expression of co-stimulatory molecules on human monocyte-derived dendritic cells (DC) as well as on ex vivo myeloid DC. Expression of co-stimulatory molecules is less pronounced on ex vivo monocytes. Production of pro-inflammatory cytokines (IL-6, TNF-α, IL-12) as well as of the anti-inflammatory cytokine IL-10 is induced in monocyte-derived DC. In PBMC cultures myeloid DC and to an even greater extent monocytes produce TNF-α and IL-6 after stimulation with GLA. Production of IL-12 can also be observed in these cultures. There are no age-related differences in the capacity of GLA to induce expression of co-stimulatory molecules or production of cytokines by human antigen-presenting cells. Therefore, TLR4 agonists like GLA are particularly promising candidates as adjuvants of vaccines designed for elderly individuals.Keywords
Funding Information
- Seventh Framework Programme (280873 ADITEC)
This publication has 45 references indexed in Scilit:
- Accessory molecules for Toll-like receptors and their functionNature Reviews Immunology, 2012
- GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older AdultsThe Journal of Infectious Diseases, 2011
- A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivoEuropean Journal of Immunology, 2011
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine AdjuvantPLOS ONE, 2011
- A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza VaccinesPLOS ONE, 2010
- Limited expansion of virus-specific CD8 T cells in the aged environmentMechanisms of Ageing and Development, 2009
- Towards an understanding of the adjuvant action of aluminiumNature Reviews Immunology, 2009
- Molecular and cellular signatures of human vaccine adjuvantsProceedings of the National Academy of Sciences, 2008
- Biology of Immune Responses to Vaccines in Elderly PersonsClinical Infectious Diseases, 2008
- Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profilingGenome Biology, 2008